ESC Premium Access

Controversies in the management of pulmonary hypertension and venous thromboembolism

Event: ESC CONGRESS 2019
Topic: Treatment
Session type: Debate Session
Date: 1 September 2019
Time: 11:00 - 12:30

Session

6 presentations in this session

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - PRO

Speaker: Professor L. Mazzolai (Lausanne, CH)
Thumbnail

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - CON

Speaker: Professor N. Meneveau (Besancon, FR)
Thumbnail

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - Discussion

Thumbnail

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - PRO

Speaker: Professor S. Rosenkranz (Cologne, DE)
Thumbnail

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - CON

Speaker: Doctor J. Bermejo Thomas (Madrid, ES)
Thumbnail

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - Discussion

Thumbnail

4 speakers from this session

Professor Lucia Mazzolai

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)
9 presentations
0 follower

Professor Nicolas Meneveau

University Hospital of Besancon - Hospital Jean Minjoz, Besancon (France)
9 presentations
0 follower

Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)
19 presentations
0 follower

Doctor Javier Bermejo Thomas

University Hospital Gregorio Maranon, Madrid (Spain)
4 presentations
0 follower

This platform is supported by

logo Novo Nordisk